← Grant listing · GrantsDue Pro
Metastasis Research Network (U54 Clinical Trial Not Allowed)
National Institutes of Health · RFA-CA-27-012 · Deadline: September 25, 2026 · Advertised ceiling: $1.3M
Program-level history — this opportunity doesn't publish per-opportunity awards, so these numbers describe its parent program (CFDA 93.396, Cancer Biology Research), not this competition alone. Labeled that way on purpose.
166 unique recipients in the sample; 90 repeat winners.
range $6k – $7.8M
Listing summary
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on developing a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the NCI will support U54 Specialized Centers that together will continue to serve as the hub of the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multidisciplinary basic research projects. The projects should use integrative system level approaches to elucid…
Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Health · official listing ↗
The full brief adds winner tables, recipient breakdowns, the printable "prepared for your client" version, and CSV export — plus a matched-grants list for your client's profile. Client Packet $79 or Pro subscription →
Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.